Significats de central adiposity en anglès

Results: Markers of total and central adiposity were positively associated with blood pressure.

The role of central adiposity and fat-free mass in endometrial cancer development remains unclear.

Further studies are needed to establish whether central adiposity contributes to risk beyond overall adiposity.

In conclusion, central adiposity may contribute to sympathetic and parasympathetic ANS declines early in life.

Several studies report genetic variants associated with central adiposity, but most utilize only European ancestry populations.

This is one of the first prospective studies focusing on central adiposity and non-Hodgkin's lymphoma subtypes.

Differences between ethnic groups in this association were observed but were explained by differences in central adiposity.

CRP was associated with measures of central adiposity and characteristics of the metabolic syndrome, particularly in women.

Background: We have shown that high mid-life central adiposity may increase the risk for dementia after 32 years.

Aging is associated with losses of lean mass and a shift to central adiposity, which are more pronounced in African Americans.

These relationships appear primarily mediated through central adiposity, highlighting the importance of maintaining a healthy weight in early adulthood to prevent CVD.

Conclusion: This study, along with several recent studies, supports the hypothesis that obesity and central adiposity are associated with pancreatic cancer risk.

Glucocorticoids play an important role in the treatment of inflammation and immune disorders, despite side effects, which include metabolic derangements such as central adiposity.

In epidemiological studies, there is little evidence regarding the relative impact of central adiposity and peripheral adiposity on cardiometabolic risk factors, especially in Asian populations.

Here we used reciprocal adoptive transfer experiments to determine whether JNK1 in myeloid cells, such as macrophages, also contributes to insulin resistance and central adiposity.

Protease inhibitors used as therapy for HIV-1 infection have been associated with metabolic side-effects such as peripheral fat wasting, central adiposity, hyperlipidaemia and insulin resistance.